ALK and lung carcinoma: Break-apart ALK FISH assay was approved by the FDA as a companion diagnostic for detecting ALK rearrangements in lung cancer patients who may benefit from treatment of ALK tyrosine kinase inhibitor therapy using ≥ 15% as a cutoff value [24].